ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "proteomics"

  • Abstract Number: 0360 • ACR Convergence 2022

    Longitudinal Variation of Proteomic Biomarkers That Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus

    Mark Lazarus1, Paul Newcombe1, Richard A. Furie2, Philip Brohawn3, Wendy White3, Dominic Sinibaldi3, Nicola Ferrari1, Raj Tummala3, Hussein Al-Mossawi1, Edward Vital4, Eric F. Morand5, Daniel Muthas6 and Madhu Ramaswamy3, 1AstraZeneca, Cambridge, United Kingdom, 2Northwell Health, Great Neck, NY, 3AstraZeneca, Gaithersburg, MD, 4University of Leeds, Leeds, England, United Kingdom, 5Monash University, Melbourne, Australia, 6AstraZeneca, Gothenburg, Sweden

    Background/Purpose: Phase 2/3 clinical trials in patients with moderate to severe SLE have demonstrated that anifrolumab, a monoclonal antibody blocking IFNAR1, produced better clinical outcomes…
  • Abstract Number: 1176 • ACR Convergence 2022

    Immunoglobulins G from Systemic Sclerosis Patients May Alter the Secretome of Dermal Fibroblasts

    Aurélien Chepy1, Marie Duhamel2, Solange Vivier3, lucile Guilbert3, Eric Hachulla4, Sylvain Dubucquoi3, David Launay3, Michel Salzet2 and Vincent Sobanski3, 1CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France, 2Univ. Lille, Inserm, CHU Lille, U1192 - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, Lille, France, 3Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France, 4University of Lille, LILLE, France

    Background/Purpose: Autoantibodies (Aab) are frequent in systemic sclerosis (SSc).Recently, it has been shown that immunoglobulins G (IgG) from SSc promoted a proinflammatory and profibrotic phenotype…
  • Abstract Number: 0386 • ACR Convergence 2022

    Quantitative Proteomic Screening Uncovers Diagnostic and Monitoring Serum Biomarkers of Ankylosing Spondylitis

    Mark Hwang1, Jessica Castillo2, kamala Vanarsa2, Jim Zheng3, Shervin Assassi4, Chandra Mohan2 and John Reveille5, 1McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, 2University of Houston, Houston, TX, 3UTHealth School of Bioinformatics, Houston, TX, 4McGovern Medical School, University of Texas, Houston, TX, 5University of Texas McGovern Medical School, Houston, TX

    Background/Purpose: We sought to discover novel serum biomarkers of ankylosing spondylitis (AS) for diagnosis and monitoring disease activity. Methods: We used biologic-treatment naïve AS and…
  • Abstract Number: 1537 • ACR Convergence 2022

    Proteomic Profiling of Plasma Microvesicles Isolated from Patients with Systemic Sclerosis

    Line Iversen1, Ole Østergaard2, Tina Friis3, susanne Ullman4, Søren Jacobsen5 and Jesper Olsen2, 1Department of Dermatology, Odense University Hospital., Odense, Denmark, 2Novo Nordisk Foundation Center for Protein Research, Copenhagen University, Copenhagen, Denmark, 3Department of Autoimmunology and Biomarkers, Statens Serum Institut, Copenhagen, Denmark, 4Department of Dermatology, Bispebjerg, Copenhagen University Hospitals, Copenhagen, Denmark, 5Department of Rheumatology, Rigshospitalet, Copenhagen University Hospitals, Copenhagen, Denmark

    Background/Purpose: In the current work, we used a mass spectrometry based proteomics workflow to analyze isolated plasma microvesicles from systemic sclerosis (SSc) patients and from…
  • Abstract Number: 0471 • ACR Convergence 2022

    Serum Proteomics in Giant Cell Arteritis: Findings of the Giant Cell Arteritis Treatment with Ultra-short Glucocorticoids and Tocilizumab Trial (The GUSTO Trial)

    Lisa Christ1, Andrea Gloor2, Florian Kollert1, Timo Gaber3, Frank Buttgereit3, Stephan Reichenbach4 and Peter Villiger5, 1Department of Rheumatology and Immunology, University of Bern, Inselspital, Bern, Switzerland, 2Department of Internal Medicine, University of Bern, Inselspital, Bern, Switzerland, 3Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany, 4University of Bern, Institute for Social and Preventive Medicine, Bern, Switzerland, 5Medical Center Monbijou, Rheumatology and Immunology, Bern, Switzerland

    Background/Purpose: Measuring disease activity in patients with giant cell arteritis (GCA) remains challenging since appropriate biomarkers are missing, particularly, if tocilizumab (TCZ) is prescribed which…
  • Abstract Number: 1632 • ACR Convergence 2022

    Novel Autoantibodies Identify Sjögren’s Disease in Patients Lacking Serum IgG Specific for Ro/SS-A and La/SS-B

    Sherri Longobardi1, Charmaine Lopez-Davis1, Bhuwan Khatri1, Constantin Georgescu1, Christina Lawrence1, Astrid Rasmussen1, Lida Radfar2, R. Hal Scofield2, Robert C. Axtell1, Gabriel Pardo1, Jonathan Wren1, Kristi A Koelsch1, Joel Guthridge1, Judith James1, Christopher Lessard1 and A. Darise Farris1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK

    Background/Purpose: Classification of Sjögren's disease (SjD) requires either Ro/SS-A autoantibodies or minor salivary gland biopsy positive for focal lymphocytic infiltrates. Up to 40% of SjD…
  • Abstract Number: 0051 • ACR Convergence 2021

    Identification of Biomarkers and Deregulated Pathways in Psoriatic Arthritis Through Proteomic Analysis of Synovial Fluid

    Jacqueline Lai1, Sara Rahmati2, Raam Sivakumar2, Katerina Oikonomopoulou3, Fatima Abji4 and Vinod Chandran5, 1McMaster University, Hamilton, ON, Canada, 2University Health Network, Toronto, ON, Canada, 3Krembil Research Institute, Toronto, ON, Canada, 4University of Toronto, University Health Network, Toronto, ON, Canada, 5Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis that currently lacks diagnostic biomarkers. We hypothesized that there are differences in the protein intensities in the…
  • Abstract Number: 0434 • ACR Convergence 2021

    Protein Profiling in Pre-dating Samples Separate MPO-ANCA Vasculitis from PR3-ANCA Vasculitis

    Mikael Brink1, Ewa Berglin1, Aladdin Mohammad2, Andrey Alexeyenko3, Kristina Lejon1 and Solbritt Rantapaa-Dahlqvist4, 1Umeå Universitet, Umeå, Sweden, 2Lund University, Lund, Sweden, 3Karolinska Institutet, Stockholm, Sweden, 4Ume University, Umea, Sweden

    Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is considered a chronic relapsing condition, with unknown etiology. This study was undertaken to gain insight to the…
  • Abstract Number: 0442 • ACR Convergence 2021

    Identification of Plexin D1 on Circulating Extracellular Vesicles as a Potential Biomarker of Polymyositis and Dermatomyositis

    Kenichi Uto1, Koji Ueda2, Takaichi Okano1, Kengo Akashi1, Soshi Takahashi3, Yuji Nakamachi4, Takamitsu Imanishi1, Seiji Kawano1, Yoshihiko Yano5 and Jun Saegusa6, 1Kobe University Hospital, Kobe, Japan, 2Japanese Foundation for Cancer Research, Tokyo, Japan, 3Shinko Hospital, Kobe, Japan, 4Kobe University School of Medicine, Kobe, Japan, 5Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan, 6Rheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan

    Background/Purpose: Extracellular vesicles (EVs), including exosomes and microvesicles, are small membrane vesicles released by almost all cell types and are found circulating in blood and…
  • Abstract Number: 0449 • ACR Convergence 2021

    Identification of Serum Protein Biomarkers at Baseline to Distinguish Radiographic Progressors from Non-Progressors in Patients with Active Psoriatic Arthritis

    Orla Coleman1, Bruna Wundervald2, Ruoyi Zhou3, James Waddington3, Robert LJ Graham4, Ciaren Graham4, Geoff McMullan4, Andrew C. Parnell5, Vinod Chandran6, Philip Mease7, Gaia Gallo8, Venkatesh Krishnan8, Stephen Pennington9 and Oliver FitzGerald10, 1Atturos, Bray, Ireland, 2Atturos, Maynooth, Ireland, 3Atturos, Belfield, Ireland, 4Queen’s University Belfast, Belfast, Northern Ireland, United Kingdom, 5Maynooth University, Maynooth, Ireland, 6Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 7Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 8Eli Lilly and Company, Indianapolis, IN, 9University College Dublin, Dublin, Ireland, 10Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland

    Background/Purpose: A delay in diagnosis and management of patients with PsA leads to poor radiographic and functional outcomes [1]. The need to identify which patients…
  • Abstract Number: 0531 • ACR Convergence 2021

    Molecular Heterogeneity Between Different Classes of Lupus Nephritis as Revealed by Kidney Biopsy Proteomics

    Asmaa AbuMaziad1, Abhimanyu Amarnani2 and Ram Singh3, 1University of California Los Angeles, Los Angeles, CA, 2Los Angeles County + University of Southern California, Los Angeles, CA, 3University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA

    Background/Purpose: Lupus nephritis (LN) causes substantial morbidity and mortality. LN is histopathologically divided into six classes, which currently serves as the basis for making treatment…
  • Abstract Number: 0546 • ACR Convergence 2021

    Integrated Analysis of Dermal Blister Fluid Proteomics and Genome-wide Skin Gene Expression Gives New Insight into Pathogenesis of Systemic Sclerosis

    Kristina Clark1, Eszter Csomor2, Corrado Campochiaro3, Adam Taylor4, Yee Voan Teo2, Katherine Nevin2, Mary Morse2, Voon Ong5, Emma Derrett-Smith6, Nicolas Wisniacki2, Shaun Flint2 and Christopher Denton7, 1University College London, London, United Kingdom, 2GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom, 3Royal Free Hospital London, London, United Kingdom, 4GlaxoSmithKline, London, United Kingdom, 5University College London Medical School Royal Free Campus, London, United Kingdom, 6University College London Division of Medicine, London, United Kingdom, 7University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom

    Background/Purpose: Suction blister fluid provides a unique opportunity to analyse the dermal microenvironment of SSc. We report an integrated analysis of proteomic data from dermal…
  • Abstract Number: 0693 • ACR Convergence 2021

    Discovery of Antigen Specific CD4+ T Cells in Anti-HMGCR-positive Immune Mediated Necrotizing Myopathy

    Eleni Tiniakou1, Andrew Mammen2 and Erika Darrah1, 1Johns Hopkins University, Baltimore, MD, 2National Institutes of Health, Bethesda, MD

    Background/Purpose: Anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR)-positive immune mediated necrotizing myopathy (anti-HMGCR+ IMNM) is a unique myopathy characterized by IgG autoantibodies against HMGCR and a strong…
  • Abstract Number: 1240 • ACR Convergence 2021

    Biomarker Driven Dissection of Inflammation Modulatory Effects of Upadacitinib versus Abatacept in Patients with Active Rheumatoid Arthritis Refractory to Biologic DMARDs

    Fang Cai1, Thierry Sornasse2, Feng Hong3, Heidi Camp4, Koji Kato5 and Iain McInnes6, 1AbbVie, Redwood City, CA, 2AbbVie Inc, Redwood City, CA, 3AbbVie, Worcester, MA, 4AbbVie Inc., North Chicago, IL, 5AbbVie Inc, Shinagawa- Ku, Japan, 6University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom

    Background/Purpose: In patients with active rheumatoid arthritis (RA) refractory to biologic DMARDs (bDMARD-IR), a phase 3, double-blind and active-controlled study (SELECT-CHOICE) demonstrated that upadacitinib (UPA)…
  • Abstract Number: 1241 • ACR Convergence 2021

    Comparison of the Effects of Upadacitinib Monotherapy with MTX on Protein Biomarkers in MTX-Naïve and MTX-Inadequate Responders in Patients with Active Rheumatoid Arthritis: Results from the SELECT-EARLY and SELECT‑MONOTHERAPY Phase 3 Studies

    Thierry Sornasse1, Heidi Camp2, Fang Cai3, Justin Klaff2 and Iain McInnes4, 1AbbVie Inc, Redwood City, CA, 2AbbVie Inc., North Chicago, IL, 3AbbVie, Redwood City, CA, 4University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom

    Background/Purpose: In MTX-naïve patients (SELECT-EARLY/M13-545 Phase 3 study) UPA 15 mg QD monotherapy (UPA Mono) demonstrated significant and clinically meaningful improvements in RA signs and…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences